BDX
Becton, Dickinson and Company
NYSE · Healthcare · Medical - Instruments & Supplies · US
$184.74
−1.54%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 20.8B | 21.8B | 20.2B | 19.4B | 18.9B |
| Cost of Revenue | 11.2B | 11.9B | 11.1B | 11.2B | 10.4B |
| Gross Profit | 9.6B | 9.9B | 9.1B | 8.2B | 8.5B |
| Operating Expenses | |||||
| R&D Expense | 1.1B | 1.3B | 1.2B | 1.2B | 1.3B |
| SG&A Expense | 5.3B | 5.3B | 4.9B | 4.7B | 4.7B |
| General & Admin Expense | 3.9B | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.1B | 806.0M | 681.0M | 103.0M | 230.0M |
| Total Operating Expenses | 7.6B | 7.3B | 6.7B | 6.1B | 6.2B |
| Cost and Expenses | 18.8B | 19.3B | 17.8B | 17.3B | 16.6B |
| Operating Income (EBIT) | 2.0B | 2.6B | 2.4B | 2.1B | 2.3B |
| Non-Operating | |||||
| Interest Income | 22.0M | 38.0M | 163.0M | 49.0M | 16.0M |
| Interest Expense | 543.0M | 613.0M | 528.0M | 452.0M | 398.0M |
| Net Interest Income | (521.0M) | (575.0M) | (365.0M) | (403.0M) | (382.0M) |
| Other Non-Op Income/Expense | (458.0M) | (696.0M) | (392.0M) | (449.0M) | (499.0M) |
| Non-Operating Income (excl Interest) | (86.0M) | 83.0M | (136.0M) | (3.0M) | 101.0M |
| EBT (Pre-Tax Income) | 1.6B | 1.9B | 2.0B | 1.7B | 1.8B |
| Income Tax Expense | 301.0M | 204.0M | 300.0M | 132.0M | 148.0M |
| Bottom Line | |||||
| Net Income | 941.0M | 1.7B | 1.7B | 1.5B | 1.8B |
| Earnings from Cont. Ops | 1.3B | 1.7B | 1.7B | 1.5B | 1.6B |
| Earnings from Discont. Ops | (348.0M) | — | — | (46.0M) | 144.0M |
| Bottom Line Net Income | 941.0M | 1.7B | 1.7B | 1.4B | 1.7B |
| Per Share | |||||
| Basic EPS | $3.32 | $5.84 | $5.88 | $4.97 | $5.93 |
| Diluted EPS | $3.32 | $5.83 | $5.86 | $4.94 | $5.88 |
| Revenue Per Share | $75.84 | $76.20 | $69.64 | $67.67 | $66.21 |
| Shares | |||||
| Basic Shares Outstanding | 274.8M | 286.6M | 289.8M | 286.3M | 285.0M |
| Diluted Shares Outstanding | 275.2M | 287.1M | 291.0M | 288.4M | 287.4M |
| Profitability Metrics | |||||
| EBITDA | 3.9B | 5.0B | 4.8B | 4.4B | 4.4B |
| D&A | 1.8B | 2.5B | 2.3B | 2.3B | 2.2B |
| EBIT | 2.1B | 2.5B | 2.5B | 2.1B | 2.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026